Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Lawrence Freedman, M.D.

Co-Author

This page shows the publications co-authored by Matthew Freedman and Toni Choueiri.
Connection Strength

2.211
  1. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.239
  2. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.236
  3. Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 Oct; 26(10):1663.
    View in: PubMed
    Score: 0.231
  4. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799.
    View in: PubMed
    Score: 0.228
  5. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
    View in: PubMed
    Score: 0.226
  6. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
    View in: PubMed
    Score: 0.224
  7. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
    View in: PubMed
    Score: 0.170
  8. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.134
  9. Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4506.
    View in: PubMed
    Score: 0.121
  10. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021 May 08.
    View in: PubMed
    Score: 0.060
  11. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genet Med. 2020 08; 22(8):1366-1373.
    View in: PubMed
    Score: 0.056
  12. Sex specific associations in genome wide association analysis of renal cell carcinoma. Eur J Hum Genet. 2019 10; 27(10):1589-1598.
    View in: PubMed
    Score: 0.053
  13. The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. PLoS Med. 2019 01; 16(1):e1002724.
    View in: PubMed
    Score: 0.051
  14. Corrigendum re "Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma" [Eur Urol 2017;72:747-54]. Eur Urol. 2018 09; 74(3):e85-e86.
    View in: PubMed
    Score: 0.049
  15. Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur Urol. 2017 11; 72(5):747-754.
    View in: PubMed
    Score: 0.046
  16. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun. 2017 06 09; 8:15724.
    View in: PubMed
    Score: 0.046
  17. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. 2016 Feb 01; 122(3):402-10.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.